Minnesota House lawmakers have voted to legalize the regulated therapeutic use of psilocybin for adults 21 and older.

The reform was added to broader health policy legislation via an amendment on the floor of the House of Representatives that was adopted by a vote of 114-15 on Thursday. The amended legislation now heads to the Senate for consideration.

The psilocybin provisions that are advancing are similar to those of a standalone bill that was approved earlier this year by the House Health Finance and Policy Committee, though that legislation had also contained language to reschedule the psychedelic under state statute, which is not part of the new amendment.

Rep. Andy Smith (DFL), who sponsored both the new amendment and the standalone bill, said on the floor that “psilocybin has shown, through a lot of wonderful research, an incredible ability to help those who are struggling with a wide variety of mental health concerns— from depression to addiction recovery, as well as PTSD, especially in veterans or public safety officers and those who have experienced a traumatic event, as well as assault survivors.”

Rep. Max Rymer (R) cited a recent psychedelics executive order signed by President Donald Trump, saying that the state legislation could help make Minnesota eligible to receive some federal funds that are being made available to support research on the issue.

“The way that I look at this amendment is it creates an offering for people to not get hooked, necessarily, into drugs on an ongoing basis, but actually use a therapeutic like this to almost rewire their brain,” he said. “The testimony that we heard firsthand, from especially a lot of our veterans, was that this was life-changing.”

Rep. Nolan West (R) said that the availability of federal funds for psychedelic research is “one of the biggest reasons to do this today.”

“Many states are in no way ready to utilize that money. So by being early, we can have a program that will help many people with severe conditions, and we’ll have it paid for by the federal government,” he said. “That money is going to be spent, and  it might as well be spent benefiting Minnesotans.”

“If you talk to a lot of veterans, or really anybody who has had this experience in this space, on how it’s helped them, it’s a unique intervention that fundamentally improves brain function and can address things unlike anything we’ve seen,” West said.

Smith also filed a similar measure last year that did not ultimately advance to enactment. He has said the legislation was informed by recommendations from a state psychedelics task force that was formed under a separate law he sponsored.

Under the current legislation, qualified patients 21 and older could receive psilocybin-assisted therapy in an approved private residence or at a licensed treatment facility.

A registered facilitator would need to administer the psychedelic. To start, the program would need to involve licensing 20 to 50 facilitators, with at least three approved testing facilities for psilocybin. No more than 1,000 patients could participate in the psychedelic therapy for the first three years of the law’s implementation.

“There are 1,000 Minnesotans right now who feel lost, who feel like potentially, that their life is over, that they can’t function,” Smith said ahead of the most recent vote. “Probably not all 1,000 will find this drug helpful, but a lot of them will, and it will lead them to a better life than they thought is possible right now.”

The Office of Cannabis Management (OCM) would be responsible for overseeing the program and establishing rules, and a new Psychedelic Medicine Advisory Committee would be established.

Psilocybin sessions would involve “preparation” with a patient-facilitator consultation, “administration” where patients would receive the psychedelic and “integration” where patients would work with professionals to process the therapeutic experience.

Kurtis Hanna, who worked as a volunteer lobbyist to pass prior legislation to establish the state’s psychedelics task force, told Marijuana Moment that he’s “extremely happy” about the latest development.

“I couldn’t have predicted that, three years later, the movement would gain this much support,” Hanna, who serves as board president for the Psychedelic Access Project, said. “Advocating for cannabis law reform over the past 17 years was difficult—we narrowly passed medical cannabis in 2014 and adult-use legalization in 2023—so it’s notable and encouraging that psychedelic law reform is resonating differently.”

Separately, the Senate Finance Committee earlier this week adopted an amendment directing OCM to “regularly analyze the availability of federal programs to provide funds to support state efforts to establish a psilocybin therapeutic use program for individuals aged 21 and older who have qualifying medical conditions to access and use psilocybin under medical supervision.”

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

Meanwhile in Minnesota, the state’s first government-run marijuana retailer recently opened its doors, marking another milestone in the state’s adult-use cannabis program.

Last September, Minnesota officials granted the state’s first-ever marijuana event organizer license, allowing adults to buy and consume cannabis products on-site at a festival. The first non-tribal marijuana shops opened for sales to adults 21 and older earlier that month.

Also last year, the Minnesota city of Eden Prairie sought suggestions from residents on what to name a new, government-branded cannabis gummy product to be sold at municipal liquor stores.

Minnesota’s House of Representatives circulated a poll at last year’s State Fair that asked attendees about the idea of allowing localities to enact bans on marijuana businesses within their borders. Most respondents who have an opinion on the issue agree with the policy, despite it not currently being a part of the state’s cannabis laws.

Ahead of the enactment of legalization in Minnesota, lawmakers’ separate State Fair polls found majority support for the reform.

The governor has also selected a top cannabis regulator for the state who will oversee the adult-use market rollout. Last June, OCM issued the state’s first recreational marijuana license for a cultivation microbusiness.

OCM said at the time that it’s taking further steps to build up in the industry and create opportunities to entrepreneurs, including opening a new licensing window for cannabis testing facilities, accepting the first applications for marijuana event licenses and verifying more social equity status requests.

Separately, after Minnesota lawmakers passed a bill to end the criminalization of bong water containing trace amount of drugs, the governor signed the measure into law last May.

The change addresses an existing policy that had allowed law enforcement to treat quantities of bong water greater than four ounces as equivalent to the pure, uncut version of whatever drug the device was used to consume.

Meanwhile, Minnesota Gov. Tim Walz (D) said in December that the state is “exploring” how to respond to an impending federal ban on hemp THC products, which would be “very disruptive” to a “thriving industry.”

Read the full psilocybin amendment adopted by the Minnesota House below:

Photo courtesy of Wikimedia/Workman.

The post Minnesota Lawmakers Pass Bill To Legalize Psilocybin Therapy appeared first on Marijuana Moment.

An Idaho medical marijuana campaign has announced that it turned in more than 150,000 signatures for a proposed legalization initiative it wants to qualify for the state’s November ballot.

The Natural Medicine Alliance of Idaho (NMAI) announced on Wednesday that it submitted the petitions ahead of last week’s deadline. County clerks across the state now have until June 30 to verify the signatures and report to the secretary of state’s office.

Amanda Watson, a spokesperson for the group, said that the petitions come from all 44 of the state’s counties and are the result of a “rigorous signature gathering effort that stretched to every corner of Idaho.”

“During the work our teams did on the ground to reach Idahoans and obtain the necessary signatures (and well beyond), we were moved and inspired by the many individuals who expressed support, shared their stories and reiterated their appreciation for the democratic process that allows for their voice to be heard through a citizen-led effort,” she said.

“This milestone belongs to the tens of thousands of Idahoans who signed,” Watson said. “Together, we have moved the Idaho Medical Cannabis Act one step closer to the ballot and one step closer to a decision made by the people of Idaho themselves. Now we await the count, and the chance to bring this issue before voters in November.”

At this stage, it’s unclear how many signatures the campaign has collected to far are valid and whether activists have met a separate requirement for regional distribution of petitions.

To be certified for the ballot, the team needs to submit signatures from at least 6 percent of registered voters as of the state’s last general election, which currently amounts to 70,725. They also need to meet that 6 percent threshold in at least 18 of the state’s 35 legislative districts.

While NMAI has pursued ballot access, Idaho lawmakers have pushed back. Both the Senate and House of Representatives passed a resolution this session urging voters to “reject” the medical marijuana petition.

The measure, sponsored by the Senate State Affairs Committee, claims that cannabis legalization in other states has led to a host of harms, including “increased cartel activity, development of black market marijuana production, human trafficking, and increased crime rates” as well as “increased rates of serious health issues,” environmental harms and “safety concerns on job sites.”

It argues that the marijuana initiative would not only increase costs to the state but that its list of approved medical conditions is “so broad that almost anyone could qualify.”

“The Idaho Medical Cannabis Act lacks safeguards to such an extent that it would effectively legalize widespread recreational use of marijuana,” the resolution claims. “The legalization of marijuana would have devastating impacts on Idaho children and their families… The Legislature urges the citizens of Idaho to reject any effort to bring the Idaho Medical Cannabis Act to the ballot.”

A statement of purpose filed with the legislation says it “addresses the devastating impact that legalizing marijuana has had on other states” and “identifies the significant problems” with the ballot initiative.

Contrary to the claims made about marijuana reform in the legislative resolution, advocates often point to data showing that legalizing and regulating cannabis diminishes the size of the illegal market and has not led to increases in youth use.

Meanwhile, NMAI recently released an analysis showing that Idaho could see more than $100 million worth of medical marijuana sold on an annual basis and up to $28 million in new yearly revenue for state coffers if voters  approve the legalization initiative.

The Idaho Medical Cannabis Act, which NMAI unveiled last October, would provide patients with qualifying conditions access to marijuana from a limited number of dispensaries and provide a regulatory framework for the market.

Here are the main provisions of the Idaho Medical Cannabis Act:

• Health practitioners would be able to recommend medical cannabis to patients with conditions that include, but are not limited to, cancer, anxiety and acute pain.
• Medical marijuana patients or their designated caregiver could purchase up to 113 grams of smokeable cannabis, or 20 grams of THC extract for vaping, per month.
• The state would be start by issuing three vertically integrated cannabis business licenses, after which point it could license up to six total.
• Marijuana would be reclassified under state law as a Schedule II, rather than Schedule I, controlled substance.
• State and local law enforcement would be barred from assisting in federal drug enforcement activities related to the state-legal cannabis program.
• There would be anti-discrimination protections for those who use or sell marijuana in compliance from state law, preventing adverse actions by employers, landlords and educational institutions.
• It does not appear that there would be any equity-centered reforms, nor would the initiative provide for a home grow option.

“We believe Idahoans deserve access to legal, compassionate, natural care right here at home,” NMAI’s website says. “Our mission is to give patients a legal pathway to natural medicine that can ease suffering and restore dignity without the fear of addiction.”

“The Idaho Medical Cannabis Act is our first step forward. It creates a safe, tightly regulated medical program that allows qualified Idahoans to seek medical cannabis treatment with a valid diagnosis from a healthcare provider,” it says. “It supports Idaho agriculture, generates tax revenue to reinvest locally, and ensures that patients can find natural relief.”

The campaign in February also released the results of a statewide poll showing that 83 percent of likely voters back medical cannabis legalization, including 74 percent of Republicans, 95 percent of Democrats and 92 percent of independents.

Asked how they would vote if the current medical cannabis legalization does appear on the November ballot, 76 percent of respondents said “yes.” Of that cohort, 50 percent said they would “definitively” vote yes, and just 21 percent said they’d vote “no.”

After the medical cannabis initiative was unveiled last year, a separate campaign that launched in 2024, Kind Idaho, told supporters that it would be suspending its own signature gathering for a ballot initiative to legalize the personal possession and cultivation of marijuana by adults.

Kind Idaho previously introduced medical marijuana ballot measures intended to go before voters in both the 2022 and 2024 elections, but the efforts proved unsuccessful.

Meanwhile, voters this year will see a different kind of proposal on the ballot: A constitutional amendment that the legislature approved to make it so only lawmakers could legalize marijuana or other controlled substances.

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

Legislators separately held a hearing last year to discuss a bill to enact medical cannabis legalization legislatively, but there hasn’t been meaningful action on the issue in the months since.

Separately, a bill from Rep. Bruce Skaug (R) last year would have set a $420 mandatory minimum fine for cannabis possession, removing judges’ discretion to apply lower penalties. Skaug said the bill, which ultimately stalled in committee, would send the message that Idaho is tough on marijuana.

House lawmakers also passed a bill to ban marijuana advertisements, though the Senate later defeated the measure.

The post Idaho Medical Marijuana Campaign Turns In 150,000 Signatures For Legalization Ballot Measure appeared first on Marijuana Moment.

A Louisiana Senate panel has advanced a bill to allow patients with terminal and irreversible conditions to use medical marijuana in hospitals.

The Senate Health and Welfare Committee approved the legislation, SB 270 from Sen. Katrina Jackson-Andrews (D), with amendments, in a voice vote on Wednesday.

“This bill was brought at the request of constituents who believe that therapeutic medical marijuana, which is already legal in this state, should be offered in hospitals when patients are terminally ill or otherwise in need the comfort of this medicine,” Jackson-Andrews said ahead of the vote.

Under the proposal, hospitals would have to create written guidelines allowing covered patients to consume medical cannabis on-site in forms other than smoking or vaping.

Under an amendment adopted by the panel, emergency or outpatient departments would be exempted from the policy. The revised legislation also clarifies that patients and primary caregivers are responsible for acquiring and administering medical marijuana, which must be “stored securely at all times in a locked container provided by the patient.”

Health care professionals and staff would be prohibited from “administering, storing, retrieving, or assisting the patient with the medical marijuana,” the text says.

The amendment, which the sponsor worked on with help from the Louisiana Hospital Association, also allows hospitals to opt out of the policy if federal officials take action against any healthcare facility in the state over medical cannabis use, rather than only allowing those that were specifically targeted to stop complying.

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

Meanwhile in Louisiana, the Senate Health and Welfare Committee last week approved a bill to create a psychedelic-assisted therapy pilot program, using opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin and ibogaine.

Lawmakers are also considering a bill to create an adult-use marijuana legalization pilot program in the state to determine whether the reform should eventually be expanded and permanently codified.

The post Louisiana Senators Approve Bill To Allow Medical Marijuana Use In Hospitals For Terminally Ill Patients appeared first on Marijuana Moment.